Lack of Histological and Molecular Signature Response to Tocilizumab in Kidney Transplants with Chronic Active Antibody Mediated Rejection: A Case Series.

Dhiren Kumar,Idris Yakubu, Frough Safavi,Marlon Levy,Irfan Moinuddin,Pamela Kimball,Layla Kamal,Anne King,Davis Massey,Philip Halloran,Gaurav Gupta

Kidney360（2020）

引用 9|浏览10

暂无评分

摘要

In this early experience, we report a lack of efficacy and toxicity with the use of TCZ for caAbMR. Prospective clinical trials are needed to clarify the role of IL-6 blockade and the possibility of increased incidence of infections in patients with caAbMR who are treated with TCZ.

查看译文

关键词

IL6 inhibition,antibody mediated rejection,chronic rejection,immunosuppression,kidney transplant,rejection,tocilizumab,transplantation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要